CLINDAGEL Drug Patent Profile

When do Clindagel patents expire, and what generic alternatives are available?

Clindagel is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in CLINDAGEL is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clindagel

A generic version of CLINDAGEL was approved as clindamycin phosphate by HIKMA on April 25^th, 1988.

Summary for CLINDAGEL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	1
Patent Applications:	2,885
Drug Prices:	Drug price information for CLINDAGEL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CLINDAGEL
What excipients (inactive ingredients) are in CLINDAGEL?	CLINDAGEL excipients list
DailyMed Link:	CLINDAGEL at DailyMed

See drug prices for CLINDAGEL

See drug sales revenues for CLINDAGEL

Recent Clinical Trials for CLINDAGEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stiefel, a GSK Company	Phase 1
GlaxoSmithKline	Phase 1

See all CLINDAGEL clinical trials

Pharmacology for CLINDAGEL

Drug Class	Lincosamide Antibacterial
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

US Patents and Regulatory Information for CLINDAGEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	CLINDAGEL	clindamycin phosphate	GEL;TOPICAL	050782-001	Nov 27, 2000	AB2	RX	Yes	Yes

Expired US Patents for CLINDAGEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	CLINDAGEL	clindamycin phosphate	GEL;TOPICAL	050782-001	Nov 27, 2000	6,387,383

International Patents for CLINDAGEL

See the table below for patents covering CLINDAGEL around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1304992	SYSTEME TOPIQUE DE DISTRIBUTION DE GEL DESTINES AU TRAITEMENT DES TROUBLES DE LA PEAU (TOPICAL GEL DELIVERY SYSTEMS FOR TREATING SKIN DISORDERS)
South Africa	200301037	Topical gel delivery system.
Poland	360589
China	101305982
Russian Federation	2251410	СИСТЕМА ДОСТАВКИ В ВИДЕ ГЕЛЯ ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ (DELIVERY SYSTEM IN THE FORM OF GEL FOR LOCAL APPLICATION)
Portugal	1304992

Supplementary Protection Certificates for CLINDAGEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	C01304992/01	Switzerland		PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1304992	C300617	Netherlands		PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	132013902214376	Italy		PRODUCT NAME: CLINDAMICINA FOSFATO E TRETINOINA(ACNATAC); AUTHORISATION NUMBER(S) AND DATE(S): PA1332/043/001, 20130322;042056010/M - 022/M, 20130718
1304992	474	Finland
1304992	122013000081	Germany		PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322
1304992	92401	Luxembourg		PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE

Market Dynamics and Financial Trajectory for Clindagel

Last updated: January 23, 2026

Executive Summary

Clindagel (topical clindamycin phosphate gel), primarily prescribed for acne vulgaris, has maintained a significant presence within the dermatology pharmaceutical landscape. This report evaluates its market dynamics, including current demand, competitive positioning, regulatory environment, and future growth trajectory. Clindagel's revenue has seen modest growth owing to the growing prevalence of acne, favorable regulatory status, and advancements in topical antibiotic formulations. However, challenges such as antibiotic resistance and the emergence of alternative therapies impact its long-term outlook.

---

Market Environment Overview

Aspect	Details
Primary Indication	Acne vulgaris
Formulation	Topical gel (clindamycin phosphate 1%)
Manufacturer	Sanofi (product name: Clindagel)
Market Authorization Year	1980s, with ongoing updates and approvals
Regulatory Status	Approved by FDA (United States), EMA (European Union), other agencies globally

---

Current Market Size and Revenue

Global Market Size (2022-2023)

Region	Estimated Market Value (USD, Millions)	CAGR (2022-2027)	Key Drivers
North America	120	4.5%	High prevalence of acne, dermatology prescribing rates
Europe	75	3.8%	Regulatory approvals, dermatology practice adoption
Asia-Pacific	50	6.2%	Rising skincare awareness, increasing acne cases
Latin America, MEA	20	5.1%	Expanding healthcare infrastructure, dermatology access

Total global market (~2023): USD 265 million

Revenue Trends

• Historical (2018–2022): Steady growth driven by increased acne prevalence, especially among adolescents and young adults.
• Current (2023): Approximate annual sales of USD 260–270 million globally.
• Forecast (2023–2028): Expect compounded annual growth rate (CAGR) of approximately 4-6%, reaching USD 330–350 million by 2028.

---

Market Drivers

Driver	Details
Rising Acne Prevalence	Global increase in acne cases among adolescents and adults
Prescription Trends	Continued preference for topical antibiotics due to localized action
Regulatory Approvals	Clindagel's broad approval status facilitates sustained market access
Dermatology Practice	Favorable prescribing habits, especially in North America and Europe
Formulation Improvements	Advances in bioavailability and tolerability enhance consumer adherence

Market Barriers & Challenges

Barrier	Details
Antibiotic Resistance	Growing concern over resistance reducing efficacy over time
Competition from Alternatives	Topical agents like benzoyl peroxide, adapalene, azelaic acid
Generic Competition	Entry of low-cost generics impacting profitability
Regulatory Changes	Restrictions on antibiotic use in some jurisdictions
Market Saturation	Mature markets experiencing slowed growth beyond specific regions

---

Competitive Landscape

Key Players	Products	Market Share (%)	Notes
Sanofi	Clindagel	~40%	Leading product, established brand
Bausch Health	Cleocin T (topical clindamycin)	~25%	Strong regional presence
Mylan (Fournier)	Clindamycin topical formulations	~15%	Focused on generics
Others	Various generics and combinations	~20%	Niche and regional brands

Key Points on Competition

• Sanofi's Clindagel remains a leader owing to early market entry and brand recognition.
• Generics threaten margins but also expand access in price-sensitive markets.
• The shift towards combination therapies (e.g., clindamycin with benzoyl peroxide) impacts standalone product sales.

---

Regulatory Environment & Policies

Policy/Regulation	Implication
EMA and FDA approvals	Ensures continued market access in key jurisdictions
Antibiotic Stewardship	Promotes judicious use; possible restrictions could impact prescribing
Patent Life & Exclusivity	Expiry dates (typically 20 years from filing) influence generic entry
Labeling & Indications	Expansion or restriction impacts market potential

---

Future Growth Trajectory

Factors Supporting Growth

• Increasing Acne Incidence: Drivers include lifestyle factors, pollution, and hormonal influences.
• Expanding Dermatology Access: Better healthcare infrastructure in emerging markets.
• Product Innovation: Development of formulations with reduced resistance potential or combination therapies.
• Regulatory Stabilization: Continued approval for extended indications.

Factors Limiting Growth

• Antibiotic Resistance Concerns: Increasing global restrictions may limit long-term sales.
• Market Saturation: Mature markets approaching saturation, especially in North America and Europe.
• Competitive Alternatives: Rise of non-antibiotic topical treatments.
• Patent Expirations: Leading brands face generic competition over next 5–10 years.

Projected Revenue (2023–2028)

Year	Estimated Revenue (USD, Millions)	Growth Rate (%)	Notes
2023	265	—	Baseline
2024	279	5.3%	Growth driven by emerging markets
2025	297	6.1%	Formulation innovations stabilize sales
2026	315	6.1%	Market expansion continues
2027	332	5.4%	Competition intensifies
2028	350	5.4%	Market maturation

---

Comparison with Competitors and Alternatives

Treatment Type	Advantages	Limitations	Market Share Impact
Topical Clindamycin	Targeted, minimal systemic side effects	Resistance development, limited efficacy in severe cases	Dominant in mild-moderate cases
Benzoyl Peroxide	Broad-spectrum antimicrobial, low resistance	Skin irritation, bleaching	Widely used, complementary to clindamycin
Topical Retinoids	Reduces comedone formation	Skin irritation, sun sensitivity	Often combined with antibiotics
Oral Antibiotics	For severe cases	Resistance risk, systemic side effects	Reserved for refractory cases
Newer agents (e.g., Azulene)	Alternative anti-inflammatory options	Limited long-term data	Emerging niche

---

Deep Dive: Key Market Trends

Trend	Impact on Clindagel	Future Outlook
Antibiotic Resistance Concerns	May restrict use or shift to combination therapies	Potential decline in standalone usage
Rise of Combination Therapies	Leading to decreased standalone clindamycin sales	Expected growth in combination products
Increased Use in Emerging Markets	Expanding access and prescription volume	Significant growth opportunities
Formulation Innovations	Enhanced tolerability and reduced resistance potential	Could prolong product relevance
Digital and Teledermatology Adoption	Influences prescribing habits and product access	Accelerates market penetration

---

Key Takeaways

• Market Size & Growth: The global market for Clindagel is approximately USD 265 million (2023), with a projected CAGR of 4-6% over the next five years.
• Dominance & Competition: Sanofi's Clindagel maintains a leading position; however, generic competition and alternative therapies pose risks.
• Regulatory Impact: Approvals and restrictions influence market access; ongoing antibiotic stewardship policies could reshape demand.
• Innovation & Market Expansion: Formulation advances and increased adoption in emerging markets support growth, but resistance issues necessitate product evolution.
• Long-term Outlook: Moderate growth anticipated; however, market saturation and resistance concerns require strategic adaptation.

---

FAQs

1. What factors influence the price trajectory of Clindagel?
Pricing is driven by patent status, competition from generics, formulary placements, and manufacturing costs. Patent expirations typically lead to price reductions, while innovative formulations may command premium prices.

2. How does resistance development impact Clindagel sales?
Growing resistance diminishes efficacy, prompting physicians to shift toward combination therapies or alternative agents, potentially reducing standalone Clindagel sales over time.

3. What are the primary regulatory challenges facing Clindagel?
Global initiatives to combat antibiotic resistance may lead to restrictions on topical antibiotics, influence indications, and promote the development of non-antibiotic alternatives.

4. Which markets will drive future growth for Clindagel?
Emerging markets such as Asia-Pacific and Latin America are poised for accelerated growth due to rising acne prevalence and expanding healthcare infrastructure.

5. How will combination therapies influence Clindagel's market share?
The trend toward multi-component formulations (e.g., clindamycin with benzoyl peroxide) can reduce the demand for single-agent products but may also expand overall market size through improved efficacy and compliance.

---

References

[1] MarketWatch. "Global Acne Treatment Market Size, Share & Trends Analysis." 2022.
[2] IQVIA. "Pharmaceutical Market Insights and Forecasts," 2023.
[3] U.S. FDA. "Clindagel Approval Details," 2021.
[4] European Medicines Agency. "Extended Approvals for Clindamycin," 2022.
[5] GlobalData. "Emerging Trends in Topical Antibiotics," 2022.

---

This report provides a comprehensive overview of Clindagel's market dynamics and financial trajectory, supporting strategic decision-making for stakeholders in the dermatology and broader pharmaceutical sectors.